CT细胞外容积与身体成分预测结直肠癌新辅助治疗反应及预后
本回顾性研究纳入163例接受新辅助治疗的结直肠癌患者,测量治疗前后增强CT定量参数及AI辅助身体成分指标。联合治疗后癌胚抗原、细胞外容积分数和骨骼肌指数的模型训练集AUC为0.836,验证集AUC为0.784。该模型产生的风险评分与总生存期和无病生存期显著相关。
要点
- 治疗后细胞外容积分数、骨骼肌指数及癌胚抗原联合模型可预测治疗反应
- 模型风险评分高者总生存期和无病生存期更短
- 治疗前后身体成分变化可作为预后评估参考指标
核心结论
- 联合治疗后癌胚抗原、细胞外容积分数和骨骼肌指数的模型或可预测结直肠癌新辅助治疗患者的治疗反应与生存结局。
研究设计与样本
- 回顾性研究纳入2016年1月至2025年6月期间接受新辅助治疗及手术的结直肠癌患者共163例,平均年龄58.50±10.55岁。
- 测量治疗前后增强CT定量参数,包括细胞外容积分数和动脉增强分数。
- 测量AI辅助身体成分参数,包括骨骼肌指数、骨骼肌衰减及内脏与皮下脂肪组织比值,并计算治疗前后变化。
- 采用逻辑回归筛选治疗反应的独立预测因素,构建多变量逻辑回归模型并以AUC评价。
- 根据模型产生的风险评分将患者分为高风险与低风险组,采用Cox回归评估风险评分与预后的关系。
关键影像表现/征象
- 增强CT可提供细胞外容积分数和动脉增强分数等定量参数。
- AI辅助身体成分分析可测量骨骼肌指数、骨骼肌衰减及内脏与皮下脂肪组织比值。
诊断标准与关键数值
- 联合治疗后癌胚抗原、细胞外容积分数和骨骼肌指数的模型训练集AUC为0.836(95% CI: 0.754-0.915)。
- 该模型验证集AUC为0.784(95% CI: 0.583-0.947)。
- 高风险组总生存期风险比为3.745(95% CI: 1.014-13.836,P=0.048)。
- 高风险组无病生存期风险比为2.801(95% CI: 1.050-7.475,P=0.040)。
临床应用与阅片要点
- 新辅助治疗后复查增强CT时可关注细胞外容积分数变化并结合骨骼肌指数评估治疗反应。
- 风险评分与生存相关,影像定量参数联合临床指标有助于分层患者预后风险。
局限性
- 本研究为回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop a combined model integrating clinical parameters, quantitative parameters from contrast-enhanced computed tomography (CECT), and Artificial Intelligence-assisted body composition metrics for predicting treatment response and prognosis in colorectal cancer (CRC) patients receiving neoadjuvant therapy (NAT).
MATERIALS AND METHODS: This retrospective study included CRC patients received NAT and surgery between January 2016 and June 2025. Quantitative CECT parameters (extracellular volume fraction [ECV] and arterial enhancement fraction), and body composition parameters (skeletal muscle index [SMI], skeletal muscle attenuation, and visceral-to-subcutaneous adipose tissue ratio) were measured before and after NAT, and their changes were calculated. Logistic regression analysis was used to identify independent predictors of treatment response. A multivariable logistic regression model was constructed, and evaluated using the area under the receiver operating characteristic curve (AUC). Patients were stratified into high- and low-risk groups based on risk score produced from the model. Cox regression analysis was used to assess association between risk score and prognosis.
RESULTS: A total of 163 patients (age, 58.50 ± 10.55 years) were included. A combined model incorporating post-NAT carcinoembryonic antigen, ECV and SMI achieved an AUC of 0.836 (95% CI: 0.754-0.915) and 0.784 (95% CI: 0.583-0.947) in the training and validation cohorts. The risk score was significantly associated with prognosis. High-risk patients had shorter overall survival (Hazard ratio [HR]: 3.745, 95% CI: 1.014-13.836, P = 0.048) and disease-free survival (HR: 2.801, 95% CI: 1.050-7.475, P = 0.040).
CONCLUSION: The combined model may help predict treatment response and survival outcomes in patients with CRC undergoing NAT.
引用
- Lu, Yuan, Zhang, et al. CT-derived extracellular volume fraction and AI-assisted body composition for predicting neoadjuvant therapy response and prognosis in colorectal cancer. Abdom Radiol (NY). 2026. PMID: 42726133. doi:10.1007/s00261-026-05718-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。